

# Kara C Long Roche

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7344514/publications.pdf>

Version: 2024-02-01

62  
papers

1,648  
citations

331538

21  
h-index

330025

37  
g-index

65  
all docs

65  
docs citations

65  
times ranked

1961  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. <i>JCO Oncology Practice</i> , 2022, 18, 201-209.	1.4	34
2	Assessment of wound perfusion with near-infrared angiography: A prospective feasibility study. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100940.	0.3	1
3	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100154.	1.0	2
4	Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues. <i>Gynecologic Oncology</i> , 2022, 165, 239-247.	0.6	9
5	Risk factors for financial toxicity in patients with gynecologic cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 817.e1-817.e9.	0.7	20
6	Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 159-164.	1.2	10
7	CT of Ovarian Cancer for Primary Treatment Planning: What the Surgeon Needs to Know. <i>Radiology</i> In Training. <i>Radiology</i> , 2022, 304, 516-526.	3.6	4
8	Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer. <i>Nature Cancer</i> , 2022, 3, 723-733.	5.7	82
9	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2021, 160, 51-55.	0.6	2
10	Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. <i>Gynecologic Oncology</i> , 2021, 160, 438-444.	0.6	9
11	Salpingectomy for the Risk Reduction of Ovarian Cancer: Is It Time for a Salpingectomy-alone Approach?. <i>Journal of Minimally Invasive Gynecology</i> , 2021, 28, 403-408.	0.3	9
12	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	9.4	139
13	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	5.8	212
14	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	0.6	2
15	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. <i>Gynecologic Oncology</i> , 2021, 161, 521-526.	0.6	2
16	Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women. <i>Gynecologic Oncology</i> , 2021, 161, 545-552.	0.6	8
17	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 687-692.	0.6	14
18	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2021, 163, 36-40.	0.6	18

#	ARTICLE	IF	CITATIONS
19	Clinical outcomes of patients with endometrioid epithelial ovarian cancer following surgical treatment. <i>Journal of Surgical Oncology</i> , 2021, 124, 846-851.	0.8	0
20	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. <i>Gynecologic Oncology</i> , 2021, 162, 345-352.	0.6	8
21	Quaternary and beyond cytoreduction: An updated and expanded analysis. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100851.	0.3	1
22	Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 222-231.	1.2	2
23	A perception-based nanosensor platform to detect cancer biomarkers. <i>Science Advances</i> , 2021, 7, eabj0852.	4.7	43
24	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. <i>Gynecologic Oncology</i> , 2020, 156, 591-597.	0.6	54
25	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. <i>Gynecologic Oncology</i> , 2020, 156, 147-153.	0.6	61
26	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	0.6	16
27	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. <i>Gynecologic Oncology</i> , 2020, 159, 66-71.	0.6	12
28	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1162-1168.	1.2	6
29	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1915-1921.	1.2	29
30	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. <i>Gynecologic Oncology</i> , 2020, 158, 608-613.	0.6	23
31	Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward or too much risk?. <i>Gynecologic Oncology</i> , 2020, 157, 561-562.	0.6	2
32	A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2020, 17, 3140-3147.	2.3	10
33	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2020, 158, 397-401.	0.6	7
34	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3772-3780.	0.7	16
35	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 418-425.	0.6	7
36	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	1.0	22

#	ARTICLE	IF	CITATIONS
37	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1183-1188.	1.2	4
38	Update on the role of surgery in the management of advanced epithelial ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2020, 18, 723-731.	0.3	3
39	State of the science: Evolving role of surgery for the treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 3-7.	0.6	7
40	Secondary surgical resection for patients with recurrent uterine leiomyosarcoma. <i>Gynecologic Oncology</i> , 2019, 154, 333-337.	0.6	14
41	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. <i>Gynecologic Oncology</i> , 2019, 154, 77-82.	0.6	24
42	A Thoughtful Pause for Sparing Oophorectomy. <i>Urology</i> , 2019, 129, 237.	0.5	0
43	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. <i>Gynecologic Oncology</i> , 2019, 154, 144-149.	0.6	24
44	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	7
45	Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center. <i>Gynecologic Oncology</i> , 2018, 149, 43-48.	0.6	10
46	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 433-437.	0.6	16
47	Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 287-293.	0.6	23
48	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. <i>Gynecologic Oncology</i> , 2018, 151, 24-31.	0.6	64
49	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	0.6	55
50	A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 27-31.	0.6	95
51	Risk-reducing salpingectomy: Let us be opportunistic. <i>Cancer</i> , 2017, 123, 1714-1720.	2.0	31
52	Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 262-266.	0.6	43
53	Surgical site infection reduction bundle in patients with gynecologic cancer undergoing colon surgery. <i>Gynecologic Oncology</i> , 2017, 147, 115-119.	0.6	31
54	Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , 2017, 147, 85-91.	0.6	74

#	ARTICLE	IF	CITATIONS
55	Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study. <i>Gynecologic Oncology Reports</i> , 2017, 22, 100-104.	0.3	28
56	“Little Big Things” A Qualitative Study of Ovarian Cancer Survivors and Their Experiences With the Health Care System. <i>Journal of Oncology Practice</i> , 2016, 12, e974-e980.	2.5	14
57	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. <i>Gynecologic Oncology</i> , 2016, 142, 13-18.	0.6	2
58	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 143, 496-503.	0.6	12
59	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. <i>Gynecologic Oncology</i> , 2016, 142, 217-224.	0.6	42
60	Is It Time to Centralize Ovarian Cancer Care in the United States?. <i>Annals of Surgical Oncology</i> , 2016, 23, 989-993.	0.7	44
61	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 246-251.	0.6	71
62	A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2014, 134, 468-472.	0.6	10